21 questions answered from cited research · Plain language
Baricitinib showed limited effectiveness for treating eye inflammation in children with juvenile idiopathic arthritis who did not respond to other standard treatments.
Read the full answer →Yes, machine learning models using registry data can predict inactive disease in juvenile idiopathic arthritis with about 70-76% accuracy, but they are not yet ready for routine clinical use.
Read the full answer →Yes, Hadlima (adalimumab) is FDA-approved to treat moderately to severely active polyarticular juvenile idiopathic arthritis in patients aged 2 years and older.
Read the full answer →In gouty arthritis, macrophages shift their energy use from oxidative phosphorylation to glycolysis and change from pro-inflammatory to anti-inflammatory states as the attack resolves.
Read the full answer →Recent reviews suggest quercetin has anti-inflammatory and antioxidant properties that could help with gout, but there is currently no strong clinical proof it works for gouty arthritis in humans.
Read the full answer →Current gout models fail because they do not fully capture the complex metabolic changes in macrophages or the chronic, multi-factorial nature of human disease.
Read the full answer →Arthritis Awareness Month is observed in May to bring attention to the condition and its impact on daily life.
Read the full answer →About 67% of U.S. adults with arthritis engage in at least one type of physical activity, though many do not meet full health guidelines.
Read the full answer →About 54.4 million U.S. adults, or 22.7% of the adult population, currently have a provider-diagnosed case of arthritis.
Read the full answer →For a walking program for adults with arthritis, Facebook was the most successful recruitment strategy, followed by radio advertisements and word of mouth.
Read the full answer →Yes, imaging — especially CT or high-resolution CT — detects interstitial lung disease in psoriatic arthritis patients more often than non-imaging methods, finding it in about 3-6% of patients.
Read the full answer →Multi-omics strategies for psoriatic arthritis combine genomics, transcriptomics, proteomics, and microbiomics to improve diagnosis, predict treatment response, and identify new drug targets.
Read the full answer →Secukinumab significantly improves skin clearance and quality of life in Chinese psoriatic arthritis patients, with PASI scores dropping from 14.2 to 4.0 after 12 weeks.
Read the full answer →Yes, smoking is associated with a higher risk of interstitial lung disease in psoriatic arthritis, with studies showing smoking as a significant risk factor.
Read the full answer →Yes, some targeted therapies for psoriatic arthritis can change your cholesterol levels, but the effect varies by drug class.
Read the full answer →Yes, secukinumab is effective for Chinese patients with psoriatic arthritis, with real-world data and cost-effectiveness analyses supporting its use.
Read the full answer →RNA methylation, especially m6A, is increased in rheumatoid arthritis and may drive synovitis by altering gene expression in joint cells, with potential as a biomarker and treatment target.
Read the full answer →Yes, sinomenine reduces arthritis markers in animal studies for rheumatoid arthritis, as shown by meta-analyses and individual rodent studies.
Read the full answer →Yes, Hadlima (adalimumab) is FDA-approved for treating moderately to severely active rheumatoid arthritis in adults.
Read the full answer →Early research suggests plant-derived extracellular vesicles may reduce inflammation in rheumatoid arthritis, but human studies are lacking.
Read the full answer →Patients with rheumatoid arthritis have a higher risk of shingles compared to the general population, with a pooled proportion of about 6% and a 30% increased risk.
Read the full answer →